Core Viewpoint - The company reported strong interim results for the six months ending June 30, 2025, with significant growth in revenue and net profit, driven primarily by its innovative drug business [1][2] Financial Performance - The company achieved revenue of 35.85 billion RMB, representing a year-on-year increase of 15.1% [1] - Net profit attributable to shareholders reached 6.04 billion RMB, up 32.2% year-on-year [2] - Adjusted net profit was 6.51 billion RMB, reflecting a growth of 21.1% [2] Business Segments - The innovative drug business contributed 27.76 billion RMB, accounting for 77.4% of total revenue, with a year-on-year increase of 26% [1] - Neuroscience revenue was 12.49 billion RMB, showing a significant increase of 37.3% [1] - Oncology revenue reached 8.74 billion RMB, marking a substantial growth of 41.1% [1] - Autoimmunity revenue remained stable at 8.78 billion RMB, with a year-on-year growth of 3.3% [1] Research and Development - The company increased its R&D investment to 10.28 billion RMB, a year-on-year increase of 68%, which now represents 28.7% of total revenue, up from 19.7% in the same period last year [2]

Core Viewpoint - The company reported a strong interim performance for the six months ending June 30, 2025, with significant revenue growth driven by its innovative drug business and strategic partnerships [1][2] Financial Performance - The company achieved revenue of 3.585 billion RMB, a year-on-year increase of 15.1% [1] - Net profit attributable to shareholders reached 604 million RMB, up 32.2% year-on-year [1] - Adjusted net profit was 651 million RMB, reflecting a growth of 21.1% year-on-year [1] - Research and development (R&D) expenses totaled 1.028 billion RMB, a substantial increase of 68%, representing 28.7% of total revenue [1] Business Segments - The innovative drug business contributed 2.776 billion RMB, accounting for 77.4% of total revenue, with a year-on-year growth of 26% [1] - Neuroscience revenue was 1.249 billion RMB, showing a robust increase of 37.3% year-on-year [1] - Oncology revenue reached 874 million RMB, marking a significant growth of 41.1% year-on-year [1] - Autoimmunity revenue remained stable at 878 million RMB, with a year-on-year increase of 3.3% [1] Strategic Developments - The company made important breakthroughs in product pipeline and commercialization, with the approval of innovative drugs such as Kewike (Dareliberine Hydrochloride Tablets) and Enzeshou (Suvorexant Injection) in China [1] - Strategic collaborations were established with international pharmaceutical companies like AbbVie, NextCure, and Idorsia, focusing on ADC, tri-antibody, and central nervous system drug development [2] - The company plans to continue focusing on core areas such as neurology, oncology, autoimmunity, and anti-infection to enhance its innovative drug R&D and commercialization capabilities [2]

Core Insights - The company reported a revenue of 3.585 billion RMB for the six months ending June 30, 2025, representing a year-on-year growth of 15.1% [1] - The innovative drug business contributed 2.776 billion RMB, accounting for 77.4% of total revenue, with a significant year-on-year increase of 26% [1] Business Performance - Neuroscience and oncology sectors showed remarkable performance, with neuroscience revenue reaching 1.249 billion RMB, a year-on-year increase of 37.3%, and oncology revenue at 874 million RMB, up 41.1% year-on-year [1] - Autoimmune revenue remained stable at 878 million RMB, reflecting a year-on-year growth of 3.3% [1] Profitability - The net profit attributable to shareholders reached 604 million RMB, a year-on-year increase of 32.2% [1] - Adjusted net profit attributable to shareholders was 651 million RMB, showing a year-on-year growth of 21.1%, indicating an improvement in profit quality [1] Research and Development - The company significantly increased its R&D investment, totaling 1.028 billion RMB in the first half of the year, a year-on-year increase of 68%, with the R&D expenditure as a percentage of revenue rising from 19.7% to 28.7% [1] Product Pipeline and Collaborations - The company achieved important breakthroughs in product pipeline and commercialization, with innovative drugs such as Kewike (Darexaban) and Enzeshou (Suvorexant) approved for market in China, enhancing its product offerings in major disease areas like insomnia and ovarian cancer [1] - The company established multiple strategic collaborations with international pharmaceutical companies such as AbbVie, NextCure, and Idorsia, making progress in the development of ADC, tri-antibodies, and central nervous system drugs [2] - The company plans to continue focusing on core areas such as neurology, oncology, autoimmune diseases, and anti-infection, aiming to enhance its innovative drug R&D and commercialization capabilities [2]

Group 1 - The company reported a revenue of RMB 3.585 billion for the six months ending June 30, 2025, representing a year-on-year increase of 15.14% [1] - Net profit reached RMB 604 million, showing a year-on-year growth of 32.2% [1] - Basic earnings per share were RMB 0.25, with adjusted profit attributable to equity shareholders amounting to RMB 651 million, a 21.1% increase compared to RMB 538 million in the same period last year [1] Group 2 - The company's portfolio of commercialized innovative drugs has expanded to ten products, including Enzhu, Aidesin, Xianbixin, Envida, Kexaila, Xianuoxin, Enlitai, Xianbixin sublingual tablets, Kewike, and Enzeshu, covering fields such as neuroscience, oncology, autoimmune diseases, and infections [1] - Innovative drug business revenue was RMB 2.776 billion, accounting for 77.4% of total revenue for the six months ending June 30, 2025 [1]

Group 1 - The core viewpoint of the article highlights the financial performance of the company, with a revenue of RMB 3.585 billion for the six months ending June 30, 2025, representing a year-on-year increase of 15.14% [1] - The net profit for the same period is reported at RMB 604 million, showing a significant year-on-year growth of 32.2% [1] - The basic earnings per share are recorded at RMB 0.25, while the adjusted profit attributable to equity shareholders is RMB 651 million, an increase of 21.1% compared to RMB 538 million in the same period last year [1] Group 2 - The company has successfully expanded its commercialized innovative drug portfolio to ten products, including Enfuvirtide®, Aidsin®, Xianbixin®, and others, covering areas such as neuroscience, oncology, autoimmune diseases, and anti-infection, indicating substantial market potential and synergistic benefits [1] - For the six months ending June 30, 2025, the revenue from innovative pharmaceuticals is reported at RMB 2.776 billion, accounting for 77.4% of the total revenue [1]

创新药业务收入人民币27.76亿元，占总收入比率77.4%，较2024年同期人民币22.03亿元增长26.0%。集 团收入主要来自业务聚焦的治疗领域。其中，神经科学领域收入人民币12.49亿元，占总收入的34.8%， 较2024年同期人民币9.09亿元增长37.3%；抗肿瘤领域收入人民币8.74亿元，占总收入的24.4%，较2024 年同期人民币6.19亿元增长41.1%；自身免疫领域收入人民币8.78亿元，占总收入的24.5%，较2024年同 期人民币8.50亿元增长3.3%；其他领域收入人民币5.84亿元，占总收入的16.3%，较2024年同期人民币 7.36亿元下降20.5%。 格隆汇8月21日丨先声药业(02096.HK)公告，截至2025年6月30日止6个月，集团录得以下未经审核的财 务业绩：收入人民币35.85亿元，较2024年同期人民币31.14亿元增长15.1%。归属于公司权益股东的利 润人民币6.04亿元，较2024年同期人民币4.57亿元增加人民币1.47亿元，增幅32.2%。每股盈利0.25元。 ...

格隆汇8月21日丨先声药业(02096.HK)公告，于2025年8月21日，董事会决议行使回购授权适时于公开市 场按不超过人民币5亿元的总金额回购股份。 ...

于2025年8月21日，董事会决议行使回购授权适时于公开市场按不超过人民币5亿元的总金额回购股份。 董事会认为在现阶段回购股份能展现公司对其业务前景的信心，并终能为公司带来益处及为股东创造价 值。此外，董事会认为公司现时拥有的财务资源足以在维持稳健财务状况的同时进行建议股份回购。 智通财经APP讯，先声药业(02096)发布公告，根据股东于2025年6月13日举行的股东周年大会上通过的 股东决议案，公司董事获授予一般授权以回购最多2.47亿股公司股份，占截至2025年6月13日已发行股 份总数10%。 ...

先声药业(02096)发布公告，根据股东于2025年6月13日举行的股东周年大会上通过的股东决议案，公司 董事获授予一般授权以回购最多2.47亿股公司股份，占截至2025年6月13日已发行股份总数10%。 于2025年8月21日，董事会决议行使回购授权适时于公开市场按不超过人民币5亿元的总金额回购股份。 董事会认为在现阶段回购股份能展现公司对其业务前景的信心，并终能为公司带来益处及为股东创造价 值。此外，董事会认为公司现时拥有的财务资源足以在维持稳健财务状况的同时进行建议股份回购。 ...

Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 （於香港註冊成立的有限公司） （「本公司」） （股份代號：2096） 提名委員會職權範圍 （根據本公司董事會於2025年8月21日通過的決議案所採納） 目 標 1. 成 立 提 名 委 員 會 之 目 標 為 協 助 本 公 司 董 事（「董 事」）會（「董事會」）物 色、挑 選 及向董事會推薦適合成為本公司董事的人選，監督評定董事會表現的程序， 以及設計、向董事會推薦並監督本公司有關提名人選的指引。 成 員 – 1 – – 2 – 5. 提名委員會每年須至少召開一次會議及於必要情況下主席要求召開更多次 數會議。 6. 提名委員會會議須由公司秘書應主席之要求召開。 7. 就定期會議及在所有其他切實可行的情況下，議程及相關委員會文件應全部 送交提名委員會全體成員。該等文件應及時並於擬舉行會議日期最少三(3) 天 前（或 協 定 的 其 他 時 間 內）送 出。 8. 處理事務之必要法定人數須為兩(2)名成員，彼等均須為獨立非執行董事。委 員會會議按正當程序召開，而出席人數達法定數目的會議即具有足夠能力行 使提名委員會 ...